Brachytherapy decreases risk of prostate cancer five-year recurrence
the ONA take:
According to results presented at the 3rd ESTRO Forum in Barcelona, Spain, researchers have found that men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later than those who received dose-escalated external beam radiotherapy.
For the study, researchers enrolled 398 men with localized prostate cancer who were at high risk for treatment failure. All patients initially received 8 months of androgen deprivation therapy followed by external beam radiotherapy to the prostate and lymph nodes.
Then, half of the patients received low-dose-rate prostate brachytherapy while the other half received additional dose-escalated external beam radiation therapy.
"This study illustrates very nicely how the best results can be obtained by combining various treatment options instead of trying to get the most out of one single modality. Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumors when combined with other techniques - in this case, androgen deprivation therapy and external bean radiation therapy," said Philip Poortmans, MD, PhD, President of ESTRO.
Men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|